

SUPPLEMENTARY MATERIAL

Title: Comparing achievement of National Psoriasis Foundation treatment targets among patients with psoriasis treated with ixekizumab versus other biologics in clinical and real-world studies

Authors: April Armstrong¹, Alvaro González-Cantero^{2,3}, Saakshi Khattri⁴, Guilherme Muzy⁵, William N. Malatestinic⁶, Anastasia Lampropoulou⁶, Meghan Feely McDonald^{4,6}, Sophia Kyoungah See⁶, Can Mert⁷, Andrew Blauvelt⁸

Affiliations: ¹University of California Los Angeles, Los Angeles, CA, USA; ²Ramón y Cajal University Hospital in Madrid, Spain; ³Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain; ⁴Mount Sinai Hospital, New York, NY, USA; ⁵Clinica Muzy, São Paulo, Brazil; ⁶Eli Lilly and Company, Indianapolis, IN, USA; ⁷HaaPACS GmbH, Schriesheim, Germany; ⁸Oregon Medical Research Center, Portland, OR, USA

Corresponding author: Andrew Blauvelt, MD, MBA, Oregon Medical Research Center, 9495 SW Locust St., Suite G, Portland, OR 97223, USA.

E-mail: ablauvelt@oregonmedicalresearch.com




Figure S2. Actual response rates and comparative adjusted odds ratios for NPF acceptable treatment responses in the overall, bio-naïve, and bio-experienced subpopulations of the real-world Psoriasis Study of Health Outcomes.

Missing data were imputed using the NRI method for proportions (%) of patients who achieved BSA $\leq 3\%$ or a $\geq 75\%$ improvement in BSA at Week 12. Adjusted odds ratios calculated using FMA. Results are statistically significant if 1 is not covered by the 95% CI for the odds ratio. *Abbreviations: bio, biologic; BSA, body surface area; CI, confidence interval; FMA, frequentist model averaging; IL-17A, interleukin-17A; NPF, National Psoriasis Foundation; NRI, non-response imputation*

Supplementary Material

	Overall US OL (N=1773)	Anti-IL- 17A (N=720)	Other Biologics (N=1053)	IXE (N=501)	SEC (N=219)	GUS (N=272)	RIS (N=230)	ADA (N=225)	UST (N=112)	TILD (N=83)	BROD (N=60)
Any current concomitant medications ^a	914 (52.0)	383 (53.7)	531 (50.8)	268 (54.3)	115 (52.5)	137 (50.7)	107 (46.7)	127 (56.7)	59 (54.1)	40 (48.2)	21 (35.0)
Anti-depressants	145 (8.2)	52 (7.3)	93 (8.9)	38 (7.7)	14 (6.4)	23 (8.5)	20 (8.7)	21 (9.4)	11 (10.1)	10 (12.0)	4 (6.7)
Anxiolytics	75 (4.3)	30 (4.2)	45 (4.3)	20 (4.0)	10 (4.6)	13 (4.8)	12 (5.2)	8 (3.6)	4 (3.7)	2 (2.4)	2 (3.3)
Drugs for acid related disorders	126 (7.2)	52 (7.3)	74 (7.1)	39 (7.9)	13 (5.9)	12 (4.4)	16 (7.0)	26 (11.6)	7 (6.4)	9 (10.8)	2 (3.3)
Drugs used in diabetes	177 (10.1)	78 (10.9)	99 (9.5)	51 (10.3)	27 (12.3)	25 (9.3)	25 (10.9)	21 (9.4)	14 (12.8)	5 (6.0)	3 (5.0)
Anti-thrombotics	96 (5.5)	40 (5.6)	56 (5.4)	30 (6.1)	10 (4.6)	10 (3.7)	9 (3.9)	15 (6.7)	11 (10.1)	7 (8.4)	2 (3.3)
Anti-arrhythmics	57 (3.2)	29 (4.1)	28 (2.7)	21 (4.3)	8 (3.7)	7 (2.6)	8 (3.5)	6 (2.7)	4 (3.7)	1 (1.2)	1 (1.7)
Antihypertensives	389 (22.1)	184 (25.8) [†]	205 (19.6)	127 (25.7)	57 (26.0)	56 (20.7)	43 (18.8)	45 (20.1)	29 (26.6)	16 (19.3)	7 (11.7)
ACE inhibitors	196 (11.1)	90 (12.6)	106 (10.1)	66 (13.4)	24 (11.0)	28 (10.4)	20 (8.7)	20 (8.9)	19 (17.6)	10 (12.0)	2 (3.3)
Calcium channel blockers	91 (5.2)	37 (5.2)	54 (5.2)	27 (5.5)	10 (4.6)	17 (6.3)	12 (5.2)	11 (4.9)	7 (6.5)	3 (3.6)	1 (1.7)

Supplementary Material

Beta-blockers	105 (6.0)	55 (7.7)*	50 (4.8)	38 (7.7)	17 (7.8)	13 (4.8)	13 (5.7)	7 (3.1)	10 (9.3)	3 (3.6)	2 (3.3)
Diuretics	94 (5.3)	50 (7.0)*	44 (4.2)	30 (6.1)	20 (9.1)	9 (3.3)	16 (7.0)	10 (4.5)	8 (7.3)	0	0
Anti-inflammatory and anti-rheumatic products	172 (9.8)	78 (10.9)	94 (9.0)	57 (11.5)	21 (9.6)	33 (12.2)	16 (7.0)	19 (8.5)	8 (7.3)	7 (8.4)	2 (3.3)
Lipid-modifying agents	215 (12.2)	96 (13.5)	119 (11.4)	68 (13.8)	28 (12.8)	29 (10.7)	27 (11.8)	31 (13.8)	12 (11.0)	12 (14.5)	3 (5.0)
Any other prescription drug	459 (26.1)	188 (26.4)	271 (25.9)	134 (27.1)	54 (24.7)	70 (25.9)	57 (24.9)	68 (30.4)	27 (24.8)	16 (19.3)	9 (15.0)
Previous non-biologic systemic therapies ^b	1101 (62.1)	420 (58.4) [†]	681 (64.7)	282 (56.4)	138 (63.0)	153 (56.3)	134 (58.3)	176 (78.2)	82 (73.2)	54 (65.1)	38 (63.3)
Acitretin	296 (16.7)	102 (14.2)*	194 (18.4)	75 (15.0)	27 (12.3)	53 (19.5)	33 (14.3)	40 (17.8)	31 (27.7)	16 (19.3)	13 (21.7)
Apremilast	119 (6.7)	50 (7.0)	69 (6.6)	38 (7.6)	12 (5.5)	19 (7.0)	14 (6.1)	16 (7.1)	7 (6.3)	7 (8.4)	4 (6.7)
Azathioprine	2 (0.1)	1 (0.1)	1 (0.1)	0	1 (0.5)	0	0	1 (0.4)	0	0	0
Cyclosporin	335 (18.9)	128 (17.8)	207 (19.7)	81 (16.2)	47 (21.5)	45 (16.5)	52 (22.6)	44 (19.6)	23 (20.5)	11 (13.3)	17 (28.3)
Fumaric acid amino esters	93 (5.2)	39 (5.4)	54 (5.1)	29 (5.8)	10 (4.6)	12 (4.4)	10 (4.3)	12 (5.3)	5 (4.5)	9 (10.8)	2 (3.3)
Hydroxyurea	1 (0.1)	0	1 (0.1)	0	0	0	0	1 (0.4)	0	0	0

Supplementary Material

Isotretinoin	2 (0.1)	0	2 (0.2)	0	0	0	0	2 (0.9)	0	0	0
Methotrexate	708 (40.0)	269 (37.4)	439 (41.7)	171 (34.2)	98 (44.7)	99 (36.4)	93 (40.4)	132 (58.7)	48 (42.9)	28 (33.7)	18 (30.0)
Mycophenolate mofetil	1 (0.1)	0	1 (0.1)	0	0	0	0	0	0	1 (1.2)	0
Steroids	22 (1.2)	14 (1.9)*	8 (0.8)	7 (1.4)	7 (3.2)	3 (1.1)	1 (0.4)	1 (0.4)	2 (1.8)	0	0
Other	65 (3.7)	17 (2.4)*	48 (4.6)	12 (2.4)	5 (2.3)	24 (8.8)	11 (4.8)	2 (0.9)	2 (1.8)	4 (4.8)	3 (5.0)
Previous biologic therapy targeting ^c											
IL-17A	170 (9.6)	54 (7.5)*	116 (11.0)	49 (9.8)	5 (2.3)	55 (20.2)	30 (13.0)	5 (2.2)	6 (5.4)	10 (12.0)	7 (11.7)
TNF	396 (22.3)	188 (26.1) [†]	208 (19.8)	128 (25.6)	60 (27.4)	80 (29.4)	56 (24.3)	11 (4.9)	26 (23.2)	10 (12.0)	16 (26.7)
IL-12/23 p40	221 (12.5)	79 (11.0)	142 (13.5)	53 (10.6)	26 (11.9)	96 (35.3)	28 (12.2)	3 (1.3)	0	8 (9.6)	7 (11.7)
IL-23 p19	29 (1.6)	14 (1.9)	15 (1.4)	12 (2.4)	2 (0.9)	1 (0.4)	8 (3.5)	1 (0.4)	0	2 (2.4)	3 (5.0)
IL-17 RA	16 (0.9)	3 (0.4)	13 (1.2)	2 (0.4)	1 (0.5)	5 (1.8)	5 (2.2)	0	0	3 (3.6)	0

Table S1. Concomitant medications and previous biologic and non-biologic therapy use among patients receiving US OL dosing in the PSoHO observational study.

All results are expressed as n (%). Percentages were calculated by $n/N \times 100\%$. Values are rounded to 1 decimal place.

The other biologics cohort (N=1053) includes GUS (N=272), RIS (N=230), ADA (N=225), UST (N=112), TILD (N=83), BROD (N=60), CZP (N=35), ETN (N=30), and INF (N=6). Individual data not shown for CZP, ETN, or INF due to low number of patients.

Supplementary Material

Abbreviations: ACE, angiotensin-converting enzyme; ADA, adalimumab; BROD, brodalumab; CZP, certolizumab; ETN, etanercept; GUS, guselkumab; IL, interleukin; IL-17A, interleukin-17A; IL-17 RA, interleukin-17 receptor A; INF, infliximab; IXE, ixekizumab; PSoHO, Psoriasis Study of Health Outcomes; RIS, risankizumab; SEC, secukinumab; TILD, tildrakizumab; TNF, tumor necrosis factor; US OL, US FDA-approved on-label; UST, ustekinumab.

[†]p-value <0.01 vs. the other biologics cohort.

*p-value <0.05 vs. the other biologics cohort.

^aInformation about concomitant medication use missing in 14 patients.

^bInformation about prior non-biologic systemic therapy use missing in 1 patients.

^cInformation about prior biologic use missing in 1 patient.